Patent Application
20110294886
This application is based upon Turkish Patent Application No. TR201004139, filed May 25, 2010, and Turkish Patent Application No. TR201005145, filed on Jun. 25, 2010, under relevant sections of 35 USC §119, the entire contents of each application being incorporated by reference herein.
The present invention relates to pharmaceutical compositions of pregabalin or a pharmaceutically acceptable salt thereof. The present invention more particularly relates to a stable controlled-release formulation of pregabalin, with a release profile of desired efficiency.
Pregabalin is an analog of gamma-aminobutyric acid (GABA). Its chemical designation is (S)-3-(aminomethyl)-5-methyl hexanoic acid, with the chemical structure illustrated below in Formula 1.
It is known that pregabalin binds to the auxiliary subunit of voltage-sensitive calcium channels in the central nervous system, thereby replacing [3H]-gabapentin. Pregabalin also reduces the release of many neurotransmitters, including pregabalin glutamate, noradrenaline, and the substance P. It is used for the treatment of epilepsy, simple or complex partial convulsion, either accompanied or not by secondary generalized convulsions, and of neuropathic pain. Various formulations of pregabalin have been developed. It is generally provided in the form of conventional capsule formulations. Posology requires such formulations to be administered twice or thrice daily.
Various applications can be found in relation to pregabalin in the patent literature.
Patent application WO2008008120, for instance, discloses a solid dosage form comprising a compacted fill material containing at least one active agent and at least one of a disintegrating agent and wetting agent.
Patent application WO2007052125 claims a pharmaceutical composition containing pregabalin or a pharmaceutically acceptable complex, salt, solvate, or hydrate thereof, and excipients such as a matrix forming agent and a swelling agent.
Patent application WO2008140459 discloses a solid dosage form comprising a compacted fill material having a pressure-sensitive multi-particulate and at least one cushioning agent. The multi-particulate and/or cushioning agent comprises at least one active agent and display(s) a weight loss less than 1% in 30 minutes according to the friability test USP 29 test #1216. The compacted fill material has a density of at least 0.5 g/ml and a tensile strength of less than 0.9 MPa.
Patent application WO2008140460, on the other hand, claims a solid dosage form comprising a compacted fill material including at least one active agent. The solid dosage form displays a weight loss of less than 1% in 30 minutes in accordance with the friability test USP 29 test #1216. Compacted fill material particles contain at least one active agent in the matrix and provide a controlled release of the active agent.
Patent application WO2008128775 claims a solid pharmaceutical composition comprising pregabalin as an active agent, together with one or more excipients. This composition is free from saccharides and comprises no further amino acids.
Patent application WO2009066325 provides a controlled release formulation comprising pregabalin or a pharmaceutically acceptable salt thereof, a hydrophobic release agent, and an excipient.
Stability-related problems do occur in a plurality of active agents, including pregabalin, under the influence of ambient and physical conditions. As disclosed in patent WO9959573, pregabalin, an amino acid derivative, undergoes cyclization and converts into a lactam form, even if normal storage conditions are provided. This is not desirable for the formulation.
Pregabalin is an active agent with quite good solubility and dissolution rate. This fact leads to fluctuations in the release profile of controlled-release formulations aimed to be developed. Such fluctuations, in turn, brings about imbalances in the blood plasma levels of active agent, and resultantly, undesired effects are produced on the subject.
Another problematic situation for pregabalin, in fact, is its absorption in the gastrointestinal tract. It has been observed that pregabalin absorption increases from the small intestine towards the large intestine, and becomes poor beyond the hepatic flexure. Conventional tablets are transferred to the hepatic flexure in about 6 hours or less, on average, thereafter losing efficiency due to poor absorption in the remaining parts of the intestine.
In result, the aforesaid drawbacks require a novelty in the art of pregabalin formulations with antiepileptic, analgesic, and anxiolytic activities.
The present invention relates to a controlled-release pregabalin formulation, gelling in the stomach and floating in gastric juice, thereby eliminating all aforesaid problems and bringing additional advantages to the relevant prior art.
Accordingly, one main object of the present invention is to obtain a stable formulation with antiepileptic, analgesic, and anxiolytic activities.
Another object of the present invention is to provide a pregabalin formulation administered orally once or twice per day.
A further object of the present invention is to ensure a high drug-absorption by retarding the advancement of the formulation through the gastrointestinal tract, thanks to a pregabalin formulation that gels in the stomach and floats in gastric juice.
Yet a further object of the present invention is to provide a stable formulation by preventing pregabalin used in the subject formulation from converting into the lactam form via cyclization.
Still a further object of the present invention is to embody a controlled-release formulation with a uniform release profile.
A controlled-release tablet formulation, gelling in the stomach and floating in gastric juice, has been developed to carry out any objects, referred to above and to emerge from the following detailed description.
In a preferred embodiment according to the present invention, this novelty is carried out with pregabalin or a pharmaceutically acceptable salt thereof, and a complex of sodium alginate and calcium chloride, or calcium alginate, or a properly-proportioned mixture thereof, for use as a controlled-release agent.
In a preferred embodiment according to the present invention, polycarbophil is also included as the controlled-release agent.
In a preferred embodiment according to the present invention, the proportion of polycarbophil to the total tablet weight is 0.01 to 2%.
In a preferred embodiment according to the present invention, the proportion of pregabalin to the total weight of the complex of sodium alginate and calcium chloride complex, or of calcium alginate, or of a properly-proportioned mixture thereof is between 0.01 to 20, preferably 0.05 to 16, and more preferably 0.1 to 15.
In a preferred embodiment according to the present invention, the proportion of sodium alginate to calcium chloride in the complex of sodium alginate and calcium chloride is 2:1.
In a preferred embodiment according to the present invention, excipients are included, comprising at least one or a mixture of glidants and lubricants.
In a preferred embodiment according to the present invention, these glidants comprise at least one or a mixture of colloidal silicone dioxide, talc, magnesium carbonate, calcium stearate, aluminum silicate, and magnesium silicate, with colloidal silicone dioxide being preferred.
In a preferred embodiment according to the present invention, magnesium stearate is included as the lubricant.
In a preferred embodiment of the present invention, the gel formulation floats in gastric juice.
Another preferred embodiment according to the present invention provides a method for preparing said pharmaceutical formulation, this method comprising the steps of:
A further preferred embodiment according to the present invention provides a method for preparing said pharmaceutical formulation, this method comprising the steps of:
Another preferred embodiment according to the present invention provides a method for preparing said pharmaceutical formulation, this method comprising the steps of:
In another preferred embodiment according to the present invention, said pharmaceutical formulation consists of the following ingredients:
Various production methods can be applied for the controlled-release formula that gels in the stomach, with the formulations indicated in the examples above.
In the direct compaction method, pregabalin is admixed together with colloidal silicone dioxide, and the resulting mixture is sieved. To this sieved powder mixture, calcium alginate or a complex of sodium alginate and calcium chloride is added, and the resulting mixture is mixed. Magnesium stearate is added to the final mixture, in which the resulting mixture is mixed and is compacted into tablets.
Using a wet granulation production method, pregabalin is admixed together with calcium alginate or a mixture of sodium alginate and calcium chloride. The mixture is wet granulated with water or water-alcohol (hydroalcoholic solution). After the wet granules are dried in a drier, they are sieved, and colloidal silicone dioxide and magnesium stearate are added to the sieved granules, wherein, the resulting mixture is mixed and compacted in the form of tablets.
In another production method, pregabalin is admixed together with calcium alginate or a mixture of sodium alginate and calcium chloride. The mixture is compacted via pre-compaction or compactor and is then sieved. To this sieved powder mixture, colloidal silicone dioxide and magnesium stearate are added, the resulting mixture is mixed and is compacted into tablets.
In the direct compression production, pregabalin, sodium/calcium alginate, dibasic calcium phosphate, colloidal silicone dioxide with large surface area are mixed together. Then to this mixture colloidal silicone dioxide and magnesium stearate are added. Finally, the mixture is compressed into tablets and coated.
Larged surface area Colloidal silicone dioxides are Aeropearl 300 (300 m2/g) and Aerosil 380 (380 m2/g))
In the wet granulation production, pregabalin, polypropylene, hydroxypropyl methyl cellulose and dibasic calcium phosphate are mixed together. Sodium/calcium alginate is granulated with hydroalcoholic solution and then dried and sieved. To these granules, colloidal silicone dioxide and magnesium stearate are added and then are mixed. Finally, the mixture is compressed into tablets and coated.
This invention has surprisingly provided a controlled-release pregabalin tablet formulation, which gels in the stomach and floats in gastric juice, the formulation being stable and having a desired release profile. The formulation according to the present invention swells upon contact with gastric juice, thereby decreasing its density enabling it to float in gastric juice. Thanks to this fact, the advancement of the formulation through the gastrointestinal tract is retarded. Thus, the advancement of the pregabalin-containing formulation through the gastrointestinal tract is delayed and its absorption is made to occur at a site in which adsorption takes place more efficiently. An ideal absorption of pregabalin occurs only at a certain site of the small intestine. Retaining the drug at an efficient absorption site enhances its bioavailability. In contrast to most other polysaccharide gels, alginate gels can develop instantaneously in the presence of divalent cations into acid gels at low pH and constant temperature. The gelling gives rise to a three dimensional network which determines the gel strength.
It is possible to make various controlled-release formulations containing pregabalin. For instance, it is possible to develop formulations which are retained in the stomach so that their advancement is delayed, or which are liquid out of the body and gel in the stomach with a volume increase. These systems, for instance, can float within stomach due to their low densities. Various excipients can be used for this purpose, such as alginates (salts thereof), gums, oil, gelling agents.
The present invention is used for treating epilepsy, pain, anxiety, diabetic neuropathy, neuropathic pain, partial seizure, social phobia, and postherpetic neuralgia.
It is further possible to use the following additional excipients in the formulation.
The pharmaceutical compositions according to the present invention may also comprise one or more pharmaceutically acceptable excipients. Such pharmaceutically acceptable excipients include, but are not restricted to fillers, binders, glidants, lubricants, disintegrants, surface active agents, preserving agents, coating agents etc., and the mixtures thereof.
Suitable binders include, but are not restricted to, at least one or a mixture of polyvinylprolidone, gelatin, sugars, glucose, natural gums, gums, synthetic celluloses, polymethacrylate, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, methyl cellulose, and other cellulose derivatives.
Suitable lubricants include, but are not restricted to, at least one or a mixture of sodium stearil fumarat, polyethylene glycol, stearic acid, metal stearates, boric acid, sodium chloride benzoate and acetate, sodium or magnesium lauryl sulfate.
Suitable coating agents include, but are not restricted to hydroxypropyl methyl cellulose, polyethylene glycol, polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), polyvinyl alcohol-like polymers, and all sorts of Opadry™, as well as pigments, dyes, titanium dioxide and iron oxide, and talc.
The present invention is hereby disclosed by referring to exemplary embodiments hereinabove. Whilst this exemplary embodiment does not restrict the object of the present invention, the latter must be assessed under the light of the foregoing detailed description.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2010004139 | May 2010 | TR | national |
| 201005145 | Jun 2010 | TR | national |
